Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(17%)
Results Posted
50%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
9
75%
Ph phase_1
1
8%
Ph phase_4
1
8%

Phase Distribution

1

Early Stage

9

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
9(81.8%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(2)
Terminated(4)
Other(4)

Detailed Status

unknown4
Withdrawn3
Completed2
Recruiting1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 29 (81.8%)
Phase 41 (9.1%)

Trials by Status

recruiting18%
unknown433%
active_not_recruiting18%
terminated18%
withdrawn325%
completed217%

Recent Activity

2 active trials
Showing 5 of 12
completedphase_2

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

NCT04428008
recruitingphase_2

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06461910
active_not_recruitingphase_2

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

NCT06056804
withdrawnphase_2

Abscopal Effect for Metastatic Colorectal Cancer

NCT02535988
unknown

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

NCT06024356
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04428008Phase 2

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

Completed
NCT06461910Phase 2

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT06056804Phase 2

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active Not Recruiting
NCT02535988Phase 2

Abscopal Effect for Metastatic Colorectal Cancer

Withdrawn
NCT06024356

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Unknown
NCT05790447Phase 2

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Unknown
NCT04487444Phase 2

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

Terminated
NCT02542930Phase 2

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Withdrawn
NCT02542137Phase 2

Abscopal Effect for Metastatic Small Cell Lung Cancer

Withdrawn
NCT02545751Phase 2

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Unknown
NCT02281266Phase 4

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Unknown
NCT00001036Phase 1

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12